A reduction of tofacitinib from 10 mg/day to 5 mg/day has been recommended for patients with chronic kidney disease (CKD), hepatic impairment, or those using drugs that inhibit cytochrome P450 3A4 [10]. Here, CYP3A4 is linked to chronic kidney disease.